Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
06 mei 2009 - 07:41
Statutaire naam
Crucell N.V.
Titel
Crucell Announces First Quarter 2009 Results
Bericht
Leiden, The Netherlands (May 6, 2009) – Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced its financial results for the first quarter of 2009, based on International Financial Reporting Standards (IFRS). These financial results are unaudited.
Highlights:
• In the first quarter of 2009 total revenues and other operating income increased 54% to €73.7 million, compared to €47.9 million in the same period of 2008. The strong quarter was driven by significant growth in sales of the pentavalent children’s vaccine Quinvaxem®.
• Aeras and Crucell announced the start of a Phase I clinical trial in infants of the jointly developed tuberculosis vaccine candidate, AERAS-402/Crucell Ad35. This is the first clinical trial designed to test this vaccine candidate in infants.
• In February 2009, the journal Science published a study that explains why Crucell's novel anti-influenza antibody is so effective against such a broad range of influenza virus subtypes, including H1N1. These characteristics make the Crucell antibody CR6261 a potentially revolutionary therapy against seasonal and pandemic flu.
• Following the success of our rabies and flu antibody programs, Crucell has obtained an exclusive license from Stanford University for the development of an antibody combination against the Hepatitis C virus.
• Our Yellow Fever vaccine Flavimun® was submitted for registration in Switzerland in March 2009. Submission in Germany is expected before the end of 2009.
• DSM and Crucell entered into an agreement with Bioceros B.V. to join their Vendor Network. Under the terms of the agreement, Bioceros will be a pre-approved cell line generation partner for licensees of the PER.C6® cell line located in the European Union.
Gerelateerde downloads
Datum laatste update: 20 december 2025